Interleukin-based therapy for glucose homeostasis and TIIDM: Interleukin-4 (IL-4) increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 30/May/2018, 6.11 am